May 18, 2011
The Sweden-based antibiotic resistance network ReAct has released video highlights and power point presentations from a recent European parliament seminar, The beginning of a new era in antibiotic development: Shaping of a new business model for life-saving innovation. Moderated by Andrew Jack of the Financial Times, the seminar provided a forum to examine new mechanisms to incentivize antibiotic development while also encouraging prudent drug use (i.e. de-linking pharmaceutical company revenues from drug sales) – one of the most vexing challenges facing the global effort to rein in antibiotic resistance.
